complications, especially type 2 diabetes mellitus (DM) and hyper-triglyceridemia, are the main responsible factors for the development of the epidemic of FLD [11] . Body mass index (BMI) is a surrogate index of body adiposity and a strong risk factor for FLD [12] . Waist circumference was hypothesized to be a predictor of FLD independently from BMI [13] . Imaging procedures and liver biopsy are the most common methods used for FLD diagnosis, but no single procedure was reliable enough [14] and liver biopsy, despite being the gold standard, it is invasive and expensive tool and has some health risks [15] . A number of indices that consist of simple measures were introduced to diagnose FLD [16] . Fatty liver index (FLI) is one of these indices developed as a convenient tool based on BMI, waist circumference (WC), triglyceride (TG), and gamma glutamyl transferase (GGT) levels [17, 18] . The current study tried to evaluate the validity of determination of FLD and estimation of serum CP at the 6th gestational week (GW) as early predictors for development of gestational DM (GDM) later on during pregnancy in nondiabetic pregnant women.
MATERIALS AND METHODS

Setting
Departments of Obstetrics & Gynecology and
Clinical Pathology, Menufia University hospitals, Menoufia governorate, Egypt
Design
Prospective Observational Study
Methodology
The study was started since Aug 2015 till December 2018; the study protocol was approved by the Local Ethical Committee and only couples signed a written fully informed consent were included in the study. All pregnant women who attended the Antenatal Outpatient Clinics (OPC), Menufia University hospital; for assurance of diagnosis of being pregnant were eligible for study inclusion. At the 6 th GW, women's demographic and clinical data were collected. Then, waist circumference was determined twice and the median of both measurements was obtained. Body weight and height were determined for calculation of BMI in kg/m 2 as weight (kg)/ height (m 2 ) and patients were classified according to BMI using the World Health Organization ranges [19] .
Baseline clinical and obstetric data were collected and verified to assure inclusion and exclusion criteria. Exclusion criteria included pre-pregnancy DM, history of previous GDM, essential hypertension, previous exposure to hepatotoxins, positive serum testing for hepatitis B or C, hepatic masses, gall bladder or biliary tree diseases. Women lost during the course of pregnancy were excluded. At the 6 th GW, all women were asked to attend the OPC next day fasting for 18 hours to give blood samples to determine baseline fasting blood glucose (FBG), triglycerides and serum levels of CP, insulin, γ-glutamyl transferase, and to undergo the 75-OGTT. The 75-OGTT entails obtaining three blood samples; a fasting sample and two samples 1-hr and 2-hrs after taking an oral snack containing 75 gm glucose for estimation of postprandial blood glucose (PPBG). All women underwent abdominal ultrasonongraphy to determine the presence of fatty liver. At the 24 th GW, women were asked to attend after overnight fasting to the OPC to give blood sample for re-estimation of serum insulin and undergo the 75-OGTT. The study plan was to include pregnant women who developed GDM at the 24 th week visit as GDM group and women who were free of GDM till the 24 th GW as control group.
Investigations
Sampling
Venous blood samples (5 ml) were collected from the antecubital vein under complete aseptic conditions and were divided into two parts: 1. The first part was put in a tube containing sodium fluoride (2 mg sodium fluoride/ ml blood) to prevent glycolysis and plasma was separated by centrifugation to be used for estimation of blood glucose levels, at hospital lab. 2. The second part was collected in plain tube, allowed to clot, centrifuged at 1500×g for 15 min and the serum was divided into two parts; one was used for immediate estimation of serum GGT and TG (at hospital lab) and the second part was collected in clean dry Eppendorf tube to be stored at -70°C until assayed.
Laboratory Investigations
Serum levels of insulin and CP were measured using enzyme linked immunosorbent assay (ELISA) kits according to the manufacturer's [24] and International association of diabetes and pregnancy study groups recommendations [25] as follows: FBG ≥92 mg/dl, 1-h BG ≥180 mg/dl and 2-h BG ≥153 mg/dl. 3. Fatty liver index (FLI) calculated by using 4 variables: BMI (kg/m 2 ), waist circumference (cm), TG (mg/ml), and GGT (U/L) and ranges from 0 to 100. A FLI value < 30 rules out FL, so needs no intervention, while FLI value ≥60 indicates FL that needs therapy and in between is the grey zone that can be adjusted by lifestyle change and dieting regimen (17). Mean FBG, 2-hr PPBG and serum insulin estimated at the 6 th GW were non-significantly higher in GDM versus control women. All women had increased blood glucose and serum insulin levels at the 24 th GW; however, the difference, in comparison to levels estimated at the 6 th GW, was non-significant (p>0.05) in control, but was significant in GDM women with significantly higher estimates compared to control women ( (p<0.001) frequency of obese women among GDM group. Moreover, mean BMI was significantly higher in GDM versus control groups. HOMA-IR score calculated at the 6 th GW defined 92 insulin resistant women with HOMA-IR score of ≥2, while 293 women had HOMA-IR score of <2. According to calculated FLI 69 women had fatty liver with FLI score >60, only 89 control women were rules out concerning FL with FLI <30, while 237 women were in the grey-zone with significantly higher frequency of women had FL among GDM than control women. Mean HOMA-IR score and FLI were significantly higher in GDM women than control women (Table 3 ). Mean at enrollment serum CP levels were significantly higher in GDM women than in controls (Fig. 2) . 
RESULTS
Table3. Clinical scores of studied women determined at time of enrolment
Data are presented as mean±SD, numbers & percentages; BMI: Body mass index; HOMA-IR: Homeostasis model assessment of insulin resistance; FLI: Fatty liver index; p indicates significance between both groups; p<0.05: indicates significant difference
Development of GDM at the 24 th GW positively correlated with FLI, serum CP, BMI and HOMA-IR score determined at the 6 th GW, in decreasing order of significance and ROC curve analysis considered these four variables as positive early predictors for later development of GDM, in the same decreasing order of significance ( Fig. 3 ). Regression analysis defined at 6 th GW high FLI and serum CP as early predictors for development of GDM at the 24 th GW ( Table 4 ). 
Table4. Statistical analyses for variables determined at the 6 th GW as early predictors for later development of GDM
DISCUSSION
At the 24 th GW, all women showed increased blood glucose measures, serum insulin, TG and GGT with subsequent increased HOMA-IR and FLI scores in comparison to 6 th GW measures, but the increase was non-significant in 338 women (controls) and was significant in 47 women (GDM group) who showed significantly higher measures compared to controls for a frequency of GDM of 12.2% among nondiabetic pregnant women. These data are in accordance with Lacaria et al. [26] and Du et al. [27] who reported prevalence rates of GDM of 10.9% and 8.5%, respectively. Through the current study, diagnosis of GDM relied on IADPSG criteria; similarly Sacks et al. [28] reported that among centers that participated in HAPO Study the frequency of GDM had ranged between 9.3 and 25.5% using the IADPSG criteria and Waters et al. [29] out of metaanalysis found 14.3% of studied pregnant women had GDM defined according to IADPSG criteria.
The obtained results are in line with Layton et al.
[30] who found women with GDM are characterized by a predominant insulin sensitivity defect than women with normal glucose tolerance and Wang et al. [31] documented that GDM recurred in more than half of subsequent pregnancies and women who had lower FPG and higher 1-h PPBG during 1 st trimester of 1 st pregnancy and developed higher 1 st trimester TG levels in subsequent pregnancy were at higher risk for GDM recurrence.
These findings indicated that pregnancy itself imposes glucogenic stresses mostly through inducing insulin resistance (IR) and affection of hepatic function as evidenced by the frequency of IR and FLD among control women despite of the concomitant within normal blood glucose levels. This could be attributed to disturbed regulatory mechanisms of carbohydrate metabolism secondary to pregnancy-induced inflammatory status as previously evidenced by Giacobbe et al. [32] who found markers of chronic inflammation are associated to GDM and IR during pregnancy. Also, Tsiotra et al.
[33] suggested that adipose tissue expression of adipokines contribute to increased IR and lowgrade inflammation concomitant with GDM.
As another explanation, Silva et al. [34] reported that the central and common mechanism of IR in GDM is defective signalling via Akt/mTOR in response to insulin. On the other hand, Hill [35] attributed peripheral IR during pregnancy to increasing maternal levels of placental variant growth hormone and attributed the progressively increasing insulin levels to the expansion of maternal pancreatic β-cell mass to increase in insulin availability as a counterbalance.
The reported high frequency of women had high FLI goes in hand with multiple recent studies, where Layton et al. [30] found women with GDM had significantly higher TG, lower HDL and higher non-esterified fatty acids in comparison to women with normal glucose tolerance and Lee et al. [36] found women who developed GDM had a higher prevalence, up to 55.6%, of radiological steatosis with higher FLI and hepatic steatosis index than women who did not develop GDM. Also, Correa et al. [37] detected significantly higher 1 st trimester concentrations of cholesterol, TG, insulin, LDL with increased HOMA-IR in pregnant women who subsequently developed GDM than those who did not develop GDM.
Furthermore, serum co-peptin (CP) levels estimated at the 6 th GW were significantly higher in women of GDM group than in control women. These data support the previously reported association between high plasma CP levels and risk of DM (38, 39) that was higher in women than in men [38] and suggesting a potential role of the AVP system in the pathophysiology of diabetes and its complications [39] . In line with obtained data, Ma et al. [40] found high CP concentrations at the 1 st prenatal visit were associated with increased risk of GDM.
However, Ebert et al. [41] found CP level was independently associated with gestational age at blood sampling and GDM remained an independent predictor of circulating CP in multivariate regression analysis, but on contrary to the results of the current study and to that reported by Ma et al. [40] ; Ebert et al. [41] , found median serum CP levels were significantly lower in women with GDM than controls of cross-matched GA and BMI. However, Ebert et al. [41] , failed to explain these results which are contradictory to that well-known about CP which is one of stress hormones [42] that is used as a marker of AVP levels and is linked to low water intake and high diabetes risk [43] . Moreover, Enhörning et al. [43] found water supplementation in habitual
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low-drinkers with high CP effectively lowers CP and FBG levels, so reducing diabetes risk
Statistical analyses of the current results defined high FLI and serum CP at the 6 th GW as significant predictors for subsequent development of GDM in studied non-diabetic women who had no history of previous GDM. In line with these findings, Ma et al. [40] using the integrated discrimination improvement statistic detected significantly increased discrimination ability for CP levels, estimated on the 1 st antenatal visit, between women with and without GDM. Recently, Lee et al. [36] found the risk of developing GDM was positively correlated with the severity of steatosis and the relationship between FLD and GDM remained significant after adjustment for metabolic risk factors and concluded that FLD in early pregnancy is an independent risk factor for GDM.
CONCLUSION
Development of GDM is closely associated with pregnancy-induced IR and is more frequent in women had FLD. Disturbed AVP system manifested by increased serum CP levels may be concomitant event or underlying cause for GDM. Calculation of FLI at the 6 th GW could discriminate women at risk for GDM later during pregnancy especially if associated with high serum CP levels. However, wider scale studies are mandatory to establish the calculated cutoff points for FLI and CP for identification of women at higher risk of GDM
